Ryvu Therapeutics S.A. (WSE: RVU)
Poland
· Delayed Price · Currency is PLN 43.60
-1.45 (-3.22%)
Nov 20, 2024, 5:00 PM CET
Ryvu Therapeutics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 91.18 | 67.3 | 68.44 | 35.41 | 36.95 | 33.72 | Upgrade
|
| Other Revenue | - | - | - | 0 | - | - | Upgrade
|
| Revenue | 91.18 | 67.3 | 68.44 | 35.41 | 36.95 | 33.72 | Upgrade
|
| Revenue Growth (YoY) | 8.28% | -1.67% | 93.25% | -4.16% | 9.58% | -34.75% | Upgrade
|
| Cost of Revenue | 18.68 | 17.55 | 17.41 | 13.73 | 8.76 | 12.8 | Upgrade
|
| Gross Profit | 72.5 | 49.74 | 51.03 | 21.69 | 28.19 | 20.92 | Upgrade
|
| Selling, General & Admin | 156.44 | 123.46 | 84.55 | 64.35 | 50.51 | 55.57 | Upgrade
|
| Other Operating Expenses | 10.38 | 12.68 | 23.08 | 23.66 | 1 | 2.85 | Upgrade
|
| Operating Expenses | 177.42 | 147.12 | 120.53 | 100.57 | 63.89 | 66.4 | Upgrade
|
| Operating Income | -104.93 | -97.38 | -69.49 | -78.89 | -35.7 | -45.49 | Upgrade
|
| Interest Expense | -2.13 | -0.1 | -1.09 | -0.44 | -0.39 | -0.4 | Upgrade
|
| Interest & Investment Income | 10.18 | 13.83 | 1.15 | 0.06 | 0.22 | 0.91 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.52 | -4.9 | -0.83 | 0.02 | -0.11 | -0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.97 | -0 | 0 | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -100.43 | -88.54 | -70.27 | -79.25 | -35.99 | -45.14 | Upgrade
|
| Gain (Loss) on Sale of Investments | -3.57 | -3.57 | -8.93 | 0.29 | 5.36 | 0.93 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.01 | 0.1 | Upgrade
|
| Pretax Income | -104 | -92.11 | -79.2 | -78.96 | -30.62 | -44.11 | Upgrade
|
| Income Tax Expense | 0.14 | - | 4.59 | 0.12 | 1.07 | 0.16 | Upgrade
|
| Earnings From Continuing Operations | -104.14 | -92.11 | -83.78 | -79.08 | -31.69 | -44.27 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | 329.91 | Upgrade
|
| Net Income to Company | -104.14 | -92.11 | -83.78 | -79.08 | -31.69 | 285.64 | Upgrade
|
| Net Income | -104.14 | -92.11 | -83.78 | -79.08 | -31.69 | 285.64 | Upgrade
|
| Net Income to Common | -104.14 | -92.11 | -83.78 | -79.08 | -31.69 | 285.64 | Upgrade
|
| Shares Outstanding (Basic) | 23 | 23 | 18 | 18 | 17 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 23 | 18 | 18 | 17 | 16 | Upgrade
|
| Shares Change (YoY) | 6.52% | 24.75% | - | 9.48% | 4.98% | 2.89% | Upgrade
|
| EPS (Basic) | -4.50 | -4.02 | -4.56 | -4.31 | -1.89 | 17.88 | Upgrade
|
| EPS (Diluted) | -4.52 | -4.02 | -4.56 | -4.31 | -1.89 | 17.88 | Upgrade
|
| Free Cash Flow | -131.68 | -93.13 | 15.07 | -70.87 | -44.82 | -41.4 | Upgrade
|
| Free Cash Flow Per Share | -5.70 | -4.07 | 0.82 | -3.86 | -2.67 | -2.59 | Upgrade
|
| Gross Margin | 79.51% | 73.92% | 74.57% | 61.24% | 76.28% | 62.03% | Upgrade
|
| Operating Margin | -115.08% | -144.70% | -101.54% | -222.76% | -96.63% | -134.89% | Upgrade
|
| Profit Margin | -114.21% | -136.88% | -122.42% | -223.30% | -85.76% | 847.09% | Upgrade
|
| Free Cash Flow Margin | -144.42% | -138.39% | 22.01% | -200.12% | -121.28% | -122.76% | Upgrade
|
| EBITDA | -95.25 | -87.32 | -58.16 | -67.94 | -26.17 | -41 | Upgrade
|
| EBITDA Margin | -104.46% | -129.76% | -84.99% | -191.85% | -70.83% | -121.57% | Upgrade
|
| D&A For EBITDA | 9.68 | 10.05 | 11.33 | 10.95 | 9.53 | 4.49 | Upgrade
|
| EBIT | -104.93 | -97.38 | -69.49 | -78.89 | -35.7 | -45.49 | Upgrade
|
| EBIT Margin | -115.08% | -144.70% | -101.54% | -222.76% | -96.63% | -134.89% | Upgrade
|
| Revenue as Reported | 91.18 | 67.3 | 68.44 | 35.41 | 36.95 | 33.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.